Finally, although the HSP90 inhibitor alvespimycin proved to be toxic in patients with AML involved in a phase I study, other therapeutic strategies using HSP90 inhibitors may be possible, specially with new inhibitors like NVP-AUY922, which seems to be less toxic than ansamycine derivaties [38, 39]. The gene discussed is HSP90AB1; the disease is acute myeloid leukemia.